GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Applied Biosciences APPB · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Popular Bitcoin Ethereum Nvidia Apple S&P 500 Gold EUR/USD US 10Y

At a glance

Figures in USD, from our data supplier.

FY2021

Revenue

$88,665

FY2014FY2021

Net income

−$767,220

FY2014FY2021

Free cash flow

−$749,718

FY2014FY2021

Shareholders' equity

−$291,056

FY2014FY2021

Income statement

Fiscal years

FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Revenue$88,665$723,351$707,062$197,554$45,554———
Operating income−$692,756−$3.1m−$2.6m−$599,530−$515,920−$28,445−$16,669−$1,822
Net income−$767,220−$4.7m−$2.6m−$2.4m−$517,656−$28,445−$16,669−$1,822
Diluted earnings per share-0.06-0.34-0.19-0.20-0.03-0.00-0.00-0.00

Balance sheet

At each fiscal year end

FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Total assets$1.3m$3.4m$3.7m$705,327$1.7m$2,191—$5,000
Cash and short-term investments$350$525,064$47,044$60,934$212,637$2,191—$5,000
Total liabilities$850,811$3.8m$374,266$35,885$31,584$41,037$13,491$1,822
Debt$272,663$387,033$25,000——$5,916——
Shareholders' equity−$291,056−$1.3m$2.1m$678,469$1.6m−$38,846−$13,491$3,178
Shares outstanding14m14m14m12m16m13m10m259m

Cash flow

Fiscal years

FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Cash from operations−$749,714−$1.2m−$905,051−$673,467−$150,835−$30,251−$14,600−$1,822
Capital spending−$4−$1,274−$1,555−$4,699−$150,000−$4,699——
Free cash flow−$749,718−$1.2m−$906,606−$678,166−$300,835−$34,950−$14,600−$1,822

Latest quarters

By quarter end

Dec 2019Sept 2019Jun 2019Mar 2019Dec 2018Sept 2018Jun 2018Mar 2018
Revenue$169,575$244,274$211,457$234,553$413,109$48,966$10,434$18,020
Operating income−$970,241−$820,847−$481,764−$409,357−$1.4m−$293,171−$558,807$117,937
Net income−$1.4m−$777,746−$423,897−$231,626−$1.9m−$110,423−$395,501−$1.7m
Diluted earnings per share-0.10-0.06-0.03-0.02-0.16-0.01-0.03-0.14
Total assets$3.4m$3.5m$3.5m$3.7m$1.8m$1.0m$806,560$705,327
Cash and short-term investments$21,268$73,412$37,940—$241,571$6,924$3,398$60,934
Debt$652,905$491,373$359,515——$78,610$2,594—
Shareholders' equity$229,272$1.2m$1.8m$2.1m$1.6m$669,002$663,599$678,469

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-23.4%——
Operating income4.9%89.4%—
Net income-31.4%93.3%—

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-465.8%-409.4%——
Net margin-670.0%-608.5%——

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-0%0%13%-58%104447%385%-31%-44%53%50%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 10-to-1 reverse split · 24 Oct 2016

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.